Articles

Drugmakers’ ‘doughnut hole’ deal to shave sales

Drugmakers including Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Co. and Eli Lilly and Co. may provide more than $2 billion in drug discounts to senior citizens next year under a deal pharmaceutical companies made with the White House.

Read More

REITs use stock sales to grow after paying debt

U.S. real estate investment trusts, including Indianapolis-based Duke Realty Corp., are selling shares to fund property acquisitions after using record cash from equity offerings last year to reduce debt and cover dividends.

Read More

Lilly wins appeal in Zyprexa case

An appeals court overturned a ruling from two years ago that granted class-action status to plaintiffs who alleged improper marketing of the schizophrenia drug.

Read More

Lilly wins reversal of class action in Zyprexa suit

A U.S. appeals court in New York threw out a September 2008 ruling that said plaintiffs could pursue as a group claims that Zyprexa marketing caused them to pay more for the drug than what it was worth. The plaintiffs were seeking $6.8 billion in damages.

Read More

Lilly investing up to $150M in VC funds

The three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each, and Lilly will contribute as much as 20 percent of the money.

Read More

Colts favored to win Super Bowl by Vegas oddsmakers

The Colts enter the regular season with 13-2 odds of capturing their second National Football League title in five years, according to Las Vegas Sports Consultants, which advises Nevada’s sports books on betting lines.

Read More

New jobless claims tick down slightly

Initial jobless claims fell by 6,000, to 472,000, in the week ended Aug. 28, in line with the median forecast of economists surveyed by Bloomberg News, Labor Department figures show.

Read More